Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study-Reference-Cited by-同舟云学术

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Published:2022-06 Issue: Volume:168 Page:12-24
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Martín Miguel^ORCID,Zielinski Christoph,Ruiz-Borrego Manuel,Carrasco Eva,Ciruelos Eva M.,Muñoz Montserrat^ORCID,Bermejo Begoña^ORCID,Margelí Mireia,Csöszi Tibor,Antón Antonio,Turner Nicholas,Casas María I.,Morales Serafín,Alba Emilio,Calvo Lourdes^ORCID,de la Haba-Rodríguez Juan,Ramos Manuel,Murillo Laura,Santaballa Ana,Alonso-Romero José L.^ORCID,Sánchez-Rovira Pedro,Corsaro Massimo,Huang Xin,Thallinger Christiane,Kahan Zsuzsanna,Gil-Gil Miguel^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer;Blum,1999

3. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer;Oshaughnessy;Ann Oncol,2001

4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer;Miller,2005

5. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines;Talbot;Br J Cancer,2002

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

2. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review;Targeted Oncology;2024-03-28

3. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer;BMC Medicine;2024-01-12

4. Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors;Journal of Chemotherapy;2023-11-09

5. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups;Annals of Oncology;2023-10